Verastem takes AbbVie’s blood cancer castoff to the FDA
A blood cancer drug that’s passed through the hands of several companies – disappointing drugmakers along the way – is finally headed to the FDA. Verastem $VSTM, a company near Boston, has filed for approval of duvelisib, a pill that blocks the well-known cancer target PI3 kinases.
The drug is meant as a treatment for patients who have blood cancers chronic lymphocytic leukemia, small lymphocytic lymphoma, or follicular lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.